Costello Medical ISPOR Presentations

ISPOR 20th Annual International Meeting, May 2015, Philadelphia, USA

**PMD34** The A System Dynamics Model for the Cost-effectiveness Evaluation of Bacterial Whole-genome Sequencing for Detecting and Monitoring Outbreaks of MRSA
Agirrezabal I, Buchanan-Hughes A, Eddowes L, Luheshi L, Sagoo GS, Török ME

**PMD37** A System Dynamics Model for the Cost-effectiveness Evaluation of Bacterial Whole-genome Sequencing for Monitoring Outbreaks of *Clostridium difficile*
Buchanan-Hughes A, Agirrezabal I, Eddowes L, Luheshi L, Török ME, Sagoo GS

**PRM28** Implication of the Inter-relatedness of the Proportional and Absolute QALY Shortfall Measurements for Disease Burden
Kusel J, Beale R, Maruszczak M

**PHP107** The WHO-Choice Cost-effectiveness Threshold: A Country-level Analysis of Changes Over Time
Griffiths M, Maruszczak M, Kusel J

ISPOR 17th Annual European Congress, November 2014, Amsterdam, The Netherlands

**W5** Value-based Assessment for NI CE: How to Do the Calculations
Kusel J, Boysen M, Hatswell AJ, Shah K

**HS3** Impact of Morbidity in Populations of North London Clinical Commissioning Groups on Patient Admission Rates and GP Referrals
Groom ZC, Burgon J, Eddowes LA, Wilson T, Kusel J

**QA1** Economic Orphans? The Prevalence of Child-specific Utilities in NI CE Appraisals for Paediatric Indications
Montgomery S, Hassan M, Kusel J

**NI 2** Predicting the Impact of Value-based Assessment on Future NI CE Appraisals
Beale RC, Maruszczak M, Kusel J

**PGI17** A Cost of Care Model for Inflammatory Bowel Disease with a UK NHS Perspective
Miles G, Leonard SA, Ghosh N, Premchand P

**PND49** Expected Value of Partial Perfect Information for the Disability Progression Efficacy of Teriflunomide and Fingolimod in the Treatment of Relapsing-remitting Multiple Sclerosis
Maruszczak M, Kusel J, Adlard N

**PMH63** Antidepressant Use and Suicide Rate in England: The Geographic Divide
Anderson R, Wilson T, Griffiths M

**PRM124** Discrete Event Simulation for the Cost-effectiveness Evaluation of PET-CT Scans in the Diagnosis of Conn's Disease in Hypertensive Patients
Maruszczak M, Stewart G, Kusel J, Brown MJ

**PRM28** Systematic Review and Critique of Health Economic Models of Relapsing-remitting Multiple Sclerosis in the UK
Kusel J, Maruszczak M, Montgomery S, Allen F, Adlard N

**PCN260** Investigating the Use of Personalised Medicine in Cancer Trials - An Update
Hamilton K, Wilson T
IP2 Disinvestment in Asia-Pacific: How Can This Be Implemented in HTA and What Can Be Learnt from Europe?
Brooks-Rooney C, Kamae I, Tan ST, Gutiérrez-Ibarluzea I

QA2 An Analysis of New Health Technologies and Reimbursement Pricing Structure in Taiwan
Stewart G, Brooks-Rooney C

PCN13 Analysing the Effects of a Disinvestment Decision in Breast Cancer Screening Programmes in Asia-Pacific Countries: A Modelling Approach
Agirrezabal I, Bunting C, Brooks-Rooney C

PCN39 The Differences Between Cancer Drug Approvals in Japan and the USA
Anderson R, Brooks-Rooney C

PDB9 Impact of Ethnicity on the Efficacy and Safety Outcomes of Anti-diabetes Drugs - Case Study of Liraglutide in Asian and Non-Asian Populations

PMS30 Closing the Gap: Reduced Delay to Drug Marketing Approval Between the West and Asia
Hamilton KI, Eddowes LA, Brooks-Rooney C

PIN33 The Differences Between Infectious & Parasitic Drug Approvals in Japan and the USA
Anderson R, Brooks-Rooney C

HC2 The Impact of NICE’s End-Of-Life Threshold on the Availability of New Cancer Therapies in England and Wales
Stewart G, Eddowes L, Hamerslag L, Kusel J

PHP27 An Update on How NICE Manage Off-Label Comparators
Kusel J, Steeves S, Maruszczak M, Pettit L, Wilson T, Taylor D

PGI30 Patterns of Generic and Proprietary Prescribing of Proton Pump Inhibitors (PPIs) Over Time in England
Hamilton K, Kusel J, Leonard S

PDB128 Insulin Pumps for the Treatment of Type 1 Diabetes Mellitus: Why is Uptake so Low in the UK?
Marsh W, Wilson T, Kusel J

IP13 Should Off-Label Agents Be Used as Comparators in Health Technology Assessments?
Kusel J, Walker W, Spackman E, Andersson C

PCN207 Impact of Recommended Pharmaceuticals on Cancer Mortality: Analysis of Real-Life Data
Wilson T, Hamerslag L, Kusel J

PHP152 The Relationship Between Scientific Research, Clinical Trials and FDA Drug Approval
Burgon J, Hamerslag L

PHP166 How Does the Uncertainty Around the Expected ICER Affect NICE Decisions?
Barber R, Steeves S, Wilson T, Hamerslag L, Kusel J

PMH68 How Well Do We Understand the Economic Burden Associated with Dementia? A Focus on Trends in Care Home Costs and Future Perspectives in the UK
Griffiths M, Hamerslag L, Wilson T, Stewart G, Kusel J

PMS27 Global Variations in Biologics Access and Rheumatoid Arthritis Treatment Costs
Miles G, Bell J, Wilson T, Hamerslag L, Kusel J
PSY89 Treatment Options in Obesity: Is Clinical Development Keeping up with an Expanding Population?
Hay J, Barber R, Kusel J, Wilson T

PMS48 Quality of Life in Rheumatoid Arthritis: How Much Do We Really Know?
Miles GA, Rolfe F, Kusel J, Brooks-Rooney C, Hay J

PHP104 Assessing the Implementation of NI CE Guidance: Is There a Correlation Between Recommendations and Uptake in Clinical Practice

NI2 The Use of Off-Label Comparators in NI CE Appraisals - An Indirect Endorsement?
Kusel J, Wong GK, Hay JA, Petitt LJ

CA2 Applying a Value-Based Price Across Different Disease Areas
Wilson TJ, Kusel J, Brooks-Rooney C, Costello S

PCN144 Access to Cancer Interventions Across the UK: To What Extent Does SMC Advice Agree with NI CE’s End-of-Life Therapies?
Hamerslag L, Brooks-Rooney C, Zhou A, Pettit L

HC4 Tapping into the Asian Pharmaceutical Market: Global Firms Go Local?

PHP82 The Characteristics of Clinical Trials in Asia
Brooks-Rooney C, Wong GKW, Hamerslag L, Costello S

PRM11 The Use of Biomarkers in Cancer Trials in Asia
Hamerslag L, Wilson T, Brooks-Rooney C

PCN148 The Use of Personalised Medicine in Cancer Trials

PHP66 Assessing Agreement Between Patient Access Schemes: Review of NI CE and SMC Guidance
Timm B, Leonard S, Haynes S

PRM11 The Rise of Budget Impact Analyses - Another Hurdle in the Health Technology Approval Process?
Wong GKW, Hamer N, Wilson T, Costello S

Hamerslag L, Haynes S, Kusel J, Costello S

RS4 The Interim Cancer Drugs Fund - How To Not Spend £50 Million
Timm B, Brooks-Rooney C, Hamerslag L, Costello S

PHP123 To What Extent Does Advice From the SMC Agree with that Published by NI CE?
Leonard SA, Brooks-Rooney C, Kusel J, Costello S

PHP145 The Burden of Evidence in the Pharmaceutical Appraisal Process

PHP152 The Administrative Burden of Patient Access Schemes in the Changing UK Healthcare System: A Follow Up Study

PRM9 What Guidance is Available for Budget Impact Analysis?
Kusel J, Leonard S, Wilson T, Costello S
ISPOR 16th Annual International Meeting, May 2011, Baltimore, MD, USA

PRM3 The Burden of Caregiving: Assessing the Status of Current Clinical Research
Hamer N, Costello S, Hamerslag L, Haynes S, Roper S

PHP5 Incentive-based Interventions - Rewarding Patients for Good Behaviour
Haynes S, Costello S, Brooks-Rooney C, Hamer N

PHP7 Developing Public Health Guidance - What are the Data Gaps? Review of the Gaps in the Evidence Identified by NI CE in the UK
Kusel J, Hamer N, Roper S, Hamerslag L, Costello S

PHP43 The Influence of Patient Access Schemes on Appraisal Decisions by NI CE in the UK

PHP8 The Implementation of Public Health Guidance: Preference for Clinical over Behavioural Interventions
Hamerslag L, Kusel J, Haynes S, Brooks-Rooney C, Costello S

PMS69 The Use of Mixed Treatment Comparisons in NI CE Technology Appraisals

ISPOR 13th Annual European Congress, November 2010, Prague, Czech Republic

NI4 Do Patient Access Schemes Result in an Acceptable Administrative Burden?
Haynes S, Costello S, Brooks-Rooney C, Hamer N

PHP94 Is it Cost-Effective to Change the Behaviour of Healthcare Professionals?

PHP98 Cost-Effectiveness Methodologies of Strategies that Aim to Change the Behaviour of Healthcare Professionals

ISPOR 15th Annual International Meeting, May 2010, Atlanta, GA, USA

PHP79 Innovative Pricing Agreements in UK NI CE Submissions
Costello S, Haynes S, Kusel J, Brooks-Rooney C, Hamer N